Lifetime follow-up care is necessary for all patients with treated thyroid nodules (multiple letters) [2]

European Journal of Endocrinology

Volumn 148, Issue 3, 2003, Pages 377-379

  Dietlein, Markus ^a   Schicha, H ^a   Vidal Trécan, Gwenaëlle M ^d   Stahl, James E ^b   Durand Zaleski, Isabelle ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HENRI MONDOR HOSPITAL   (France)

^d Universite René Descartes ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; RADIOACTIVE IODINE; THYROTROPIN;

CANCER MORTALITY; CANCER RISK; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DYSPHONIA; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; HYPOTHYROIDISM; IODINE 131 UPTAKE TEST; LETTER; LONG TERM CARE; MALE; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; SUBTOTAL THYROIDECTOMY; THYROID CANCER; THYROID NODULE;

COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; HEALTH RESOURCES; HUMANS; IODINE RADIOISOTOPES; QUALITY OF LIFE; THYROID NODULE;

EID: 0037360444     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1480377     Document Type: Letter

References (0)